Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Delpazolid - LigaChem Biosciences

Next Previous
Drug Profile

Delpazolid - LigaChem Biosciences

Alternative Names: DPZ; LCB-01371; LCB01-0371; RMX 2001

Latest Information Update: 08 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LegoChem Biosciences
  • Developer HaiHe Biopharma; LigaChem Biosciences
  • Class Antibacterials; Oxazolidinones; Small molecules; Triazines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bacteraemia; Tuberculosis
  • No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 16 Feb 2024 LigaChem Biosciences terminates a phase II trial in Bacteraemia (Combination therapy, In adults, In the elderly) in South Korea (PO) due to difficulties in enrolling subjects due to the decrease in patients with MRSA bacteremia (NCT05225558)
  • 23 Aug 2023 LegoChem Biosciences plans a phase IIa trial in Nontuberculous mycobacterium infections (Adjunctive therapy) (PO, Tablet) in December 2023 (NCT06004037)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Gram-positive-infections in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top